查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1856610

鴉片類藥物引起的便秘市場（依產品類型分類：口服、直腸給藥）－2025-2032年全球預測

Opioid Induced Constipation Market by Product Type, Oral, Rectal - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，鴉片類藥物引起的便秘市場規模將成長 1.1994 億美元，複合年成長率為 6.94%。

關鍵市場統計數據
基準年 2024 7010萬美元
預計年份：2025年 7503萬美元
預測年份 2032 1.1994億美元
複合年成長率 (%) 6.94%

將鴉片類藥物引起的便秘視為一項亟待解決的臨床品質和病患體驗問題，需要整合式照護路徑和產品創新。

鴉片類藥物引起的便秘 (OIC) 是鴉片類藥物治療的一種持續且複雜的併發症，會影響患者的依從性、生活品質和臨床療效。由於鴉片類藥物處方仍然是急性和慢性疼痛管理的重要組成部分，OIC 已成為可預測的副作用，需要積極評估和全面管理策略。臨床醫生、付款者和產品開發人員必須兼顧有效緩解疼痛和保護胃腸道功能的雙重需求，從而推動新的臨床路徑和支持性護理創新。

現代醫療實踐越來越強調分階段介入方法，首先是早期識別風險，然後制定個人化的預防方案、生活方式指導和選擇合適的瀉藥，最後根據需要升級到標靶藥物。同時，支付方和醫療系統也在重新評估藥品目錄、報銷政策和價值框架，以納入與腸道功能相關的病患報告結局。本引言為後續重點討論治療層級、劑型、區域市場促進因素以及相關人員在尋求改善患者結局的同時，如何確保鴉片類藥物的充足供應等戰略考慮奠定了基礎。

快速發展的臨床實踐、支付方參與、數位監測和製劑創新正在推動鴉片類藥物引起的便秘管理進入一個新時代。

在臨床、監管和患者體驗等多方面因素的驅動下，鴉片類藥物引起的便秘（OIC）管理格局正在經歷多項變革。首先，臨床治療正朝著標靶機制的治療方法旨在解決受體介導的便秘問題，同時又不影響中樞鎮痛效果。這種轉變正在改變處方模式，並促使臨床醫生在治療早期考慮使用周邊作用的μ-鴉片受體拮抗劑。其次，患者的期望和數位化醫療的普及正在重塑便秘的報告、監測和管理方式。行動症狀追蹤和遠端醫療追蹤正日益融入治療方案中，從而能夠更快地調整治療方案。

第三，隨著醫療系統尋求量化鴉片類藥物治療對患者再入院率、住院時長和鴉片類藥物依從性等後續影響，支付方的參與度日益提高。因此，處方和用藥管理也在不斷發展，以反映臨床效用和真實世界療效的證據。第四，劑型和聯合治療的創新正在擴大臨床醫師的治療選擇。最後，疼痛專家、胃腸病學家和基層醫療醫師之間的多學科合作日益普遍，從而支持從鴉片類藥物治療開始，貫穿常規隨訪和適應症擴展的綜合路徑。這些轉變共同創造了一個環境，​​在這個環境中，臨床療效、以病人為中心的結果和經濟因素相互交織，共同指南未來的投資和實踐模式。

2025年關稅改革如何重塑藥品採購、供應鏈韌性與籌資策略，進而影響OIC療法的可近性與成本動態

2025年關稅政策和跨境貿易考量給鴉片類藥物誘導性膽汁淤積症（OIC）治療相關的藥品原料和成品的供應鏈帶來了巨大壓力。面對不斷上漲的進口成本，生產商透過最佳化供應鏈、在地採購策略和戰術性庫存調整等方式來應對，以降低價格波動並維持供應的連續性。這些因應措施也促使業界更加關注區域性製造地，以減輕關稅引發的成本波動影響，並建構更具韌性的經銷網路。

同時，醫院和經銷商的採購團隊正在調整合約策略，優先考慮多供應商和長期協議，以減輕短期關稅波動的影響。臨床相關人員注意到某些品牌學名藥（尤其是特殊製劑）的供應受到間歇性影響，因此在臨床適用的情況下，需要使用替代藥物和給藥途徑。政策主導的成本壓力促使人們重新關注成本效益評估、基於價值的協議談判以及對供應鏈透明度的更嚴格審查。總而言之，2025年的關稅環境凸顯了在整個OIC治療生態系統中採取靈活的籌資策略、積極主動的相關人員溝通以及製定綜合應急計畫的必要性。

細分的治療和製劑概況揭示了聯合治療、瀉藥類別、受體拮抗劑和給藥途徑的臨床、耐受性和商業性動態

透過詳細的市場細分方法，可以揭示治療層級和劑型之間的關鍵臨床和商業差異，從而有助於制定標靶策略。按產品類型分類，市場包括：聯合治療（多種藥物混合使用，可協同控制腸道功能）；傳統瀉藥（又細分為滲透性瀉藥、刺激性瀉藥和具有不同作用機制的糞便軟化劑）；以及外周作用的μ-鴉片受體拮抗劑，包括阿維莫潘、甲基納曲酮、納美地林和納洛昔醇等分子類型，這些特徵和臨床動力學​​特徵具有不同的藥物和臨床動力學​​。這些產品層面的差異對臨床路徑、製劑偏好和實際耐受性具有重要意義。

在考慮口服給藥途徑時，製劑可分為液體和固態兩種形式。液體製劑包括溶液和混懸劑，便於劑量調整，並能幫助兒童和吞嚥困難的患者；固態製劑包括膠囊和片劑，因其便利性和依從性，在門診環境中更受歡迎。直腸給藥，如灌腸劑或塞劑，可在急診和安寧療護中快速起效，發揮著雖小但重要的作用。跨領域因素，包括病患的人口統計特徵、共病、特定給藥途徑的起效時間和製劑耐受性，指南臨床醫師的選擇和支付方的定價。了解這些多層次細分市場的動態變化，有助於制定更精準的臨床指南、處方策略和商業計劃，使產品屬性與患者的實際需求相符。

醫療保健系統、報銷重點和處方習慣方面的區域差異將影響全球市場的接受度、取得策略和臨床應用模式。

區域動態對鴉片類藥物引起的便秘的治療可近性、臨床醫生行為和政策應對措施有顯著影響，美洲、中東和非洲以及亞太地區的情況各有不同。在美洲，綜合醫療體系和大型私人支付方市場重視臨床療效和病患報告指標，推動了標靶藥物療法的早期應用，並支持對依從性項目和數位監測的投資。該地區的監管路徑也會影響適應症，進而影響臨床應用和報銷的討論。

區域差異正在影響歐洲、中東和非洲的醫療實踐模式。一些國家醫療體系優先考慮成本控制和集中採購，而另一些則強調與臨床指南和專科轉診途徑保持一致。這些差異導致先進藥物和傳統瀉藥的使用模式各不相同。在亞太地區，醫療基礎設施的快速發展、專科醫療服務覆蓋範圍的擴大以及法律規範的不斷完善，為標靶治療的推廣應用創造了新的機遇，而成本敏感性和藥物製劑供應的差異則影響著各地區的處方策略。在所有地區，人口趨勢、鴉片類藥物處方規範和醫療體系優先事項相互作用，共同決定治療方法的定位以及相關人員如何實施教育和推廣計劃。

隨著傳統製藥公司、專科創新藥廠、學名藥和數位醫療合作夥伴尋求差異化的市場准入和實證策略，它們之間逐漸形成競爭動態。

鴉片類藥物誘導性膽管炎（OIC）治療領域的競爭格局由成熟的製藥創新企業、專業生物技術公司和非專利藥生產商共同塑造，它們各自為治療方法的選擇和市場發展做出貢獻。大型製藥企業憑藉其規模優勢、廣泛的分銷網路以及與支付方和醫療服務提供者建立的穩固關係，能夠快速實現新藥的商業化，並支持大量上市後證據的積累。專業生物技術公司通常採用以新型分子和機制為導向的創新方法，這種方法具有變革治療模式的潛力，尤其是在強大的臨床差異化和標靶標記的支持下。

學名藥生產商和契約製造生產商正在推動價格競爭，並提高藥品可及性，尤其是在成本是主要障礙的地區和醫療環境中。除了傳統競爭對手之外，數位療法和遠端監測供應商等非製藥企業也在影響病人參與和真實世界療效評估，從而創造了夥伴關係機會。這些相關人員的成功越來越取決於他們建立真實世界證據、展現以病人為中心的益處以及應對複雜的支付方環境以獲得有利的報銷和納入醫保目錄的能力。

為相關人員提供切實可行的策略建議，以加強證據產生、病患可及性、製劑多樣性、供應彈性以及合作商業化方法。

為了改善鴉片類藥物引起的便秘（OIC）管理的患者療效和商業性表現，行業、臨床和支付方領導者應採取協同行動。首先，應優先產生和傳播真實世界證據，將症狀控制與疼痛治療方案依從性和醫療資源利用率降低等有意義的療效聯繫​​起來。其次，應投資於以患者為中心的製劑和給藥模式，以滿足特定需求，例如為弱勢群體提供液體製劑，為急診環境提供直腸製劑，同時考慮聯合治療以簡化治療流程。

第三，我們將加強跨相關人員的教育舉措，利用數位化工具進行症狀追蹤和遠端隨訪，以協調處方醫生的知識、護理實踐和患者自我管理。第四，我們將透過多元化採購來源、建立區域製造夥伴關係關係以及協商靈活的採購合約來增強供應鏈韌性，從而減輕政策干擾的影響。最後，我們將探索創新藥廠、學名藥公司和數位醫療公司之間的策略聯盟，以在提高治療效果的同時，改善病人參與。這些綜合措施將有助於將鴉片類藥物引起的便秘（OIC）管理有效整合到整體疼痛治療方案中，從而增強我們的商業性地位。

採用透明的多來源研究途徑，整合臨床證據、監管影響、專家諮詢和供應鏈分析，以提供有意義的見解和可行的建議。

本調查方法採用多源方法，結契約儕審查的臨床文獻、監管文件、專家臨床訪談、支付方政策分析以及主要相關人員諮詢，旨在對鴉片類藥物引起的便秘（OIC）管理形成平衡且實用的觀點。研究優先考慮臨床文獻和指南審查，以確定治療層級的標準治療方案和作用機制；同時，監管文件為附加檔、適應症和安全性資訊提供了背景。對疼痛專家、胃腸病學家、處方集管理人員和藥劑師的專家訪談，則為分析提供了真實世界的實踐模式、耐受性考量和採購動態等方面的資訊。

為了補充定性研究結果，我們對產品系列、製劑供應和供應鏈安排進行了結構化審查，以獲取商業和營運方面的觀察資料。調查方法強調資訊來源交叉驗證，以檢驗研究結果並識別共同的主題，確保研究洞察既反映臨床實際情況，也兼顧營運限制。在整個研究過程中，我們始終避免依賴任何單一資訊來源，並透明地記錄各項假設和局限性，以便讀者能夠基於適當的證據來解讀我們的研究結果。

結論性觀點，整合臨床要務、證據優先事項和策略行動，以減輕病人負擔，同時維持適當的鴉片類藥物使用。

鴉片類藥物引起的便秘 (OIC) 問題處於臨床需求、患者體驗和商業性機會的交匯點。標靶藥物藥理學、不斷變化的支付方期望以及數位化患者互動工具的融合，為相關人員提供了一個有利的環境，使他們能夠將 OIC 管理重新定義為負責任的鴉片類藥物治療的重要組成部分。臨床醫生在積極預防和早期升級治療策略方面具有優勢，而製造商和支付方必須攜手合作，協調各種患者需求的獲取途徑和價值論證。

展望未來，能夠將可靠的臨床證據、靈活的給藥模式和以患者為中心的劑型整合到連貫的商業和臨床策略中的公司，最有可能取得成功。透過優先考慮真實世界的結果、製劑的多樣性以及系統層面的協作，相關人員既可以確保患者獲得必要的鴉片類鎮痛藥，又能減輕鴉片類藥物引起的便秘（OIC）對患者和醫療保健系統帶來的負擔。這一結論強調了在臨床、商業和政策領域開展協調行動的必要性，以改善醫療品質和患者的生活品質。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 住院患者慢性癌痛管理中周邊μ-鴉片受體拮抗劑的使用增加
  • 在門診環境中推廣針對鴉片類藥物引起的便秘的新型口服小分子療法
  • 將數位治療方法與行動醫療應用程式結合，用於即時監測鴉片類藥物引起的便秘嚴重程度。
  • 增加對含有緩解便秘機制的緩釋性鴉片類藥物組合藥物的投資
  • 近期FDA擴大納洛昔醇和納多美明標籤適應症對鴉片類藥物引起的便秘治療流程的影響
  • Linaclotide和Plecanatide在仿單標示外治療鴉片類藥物引起的便秘（除大腸激躁症外）方面的市場滲透率
  • 採用以患者為中心的報銷模式，以改善患者獲得昂貴的鴉片類藥物引起的便秘治療的機會。
  • 臨床指引倡導對安寧療護人群中的鴉片類藥物引起的便秘早期療育，其影響
  • 遠端醫療諮詢在最佳化農村醫療機構鴉片類藥物引起的便秘管理策略中的作用
  • 非處方鴉片類藥物引起的便秘藥物的出現及其對處方藥市場動態的影響

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 鴉片類藥物引起的便秘市場（依產品類型分類）

  • 聯合治療
  • 瀉藥
    • 滲透性瀉藥
    • 刺激性瀉藥
    • 軟便劑
  • 周邊作用的μ-鴉片受體拮抗劑
    • 阿維莫潘
    • 甲基納曲酮
    • 納美地林
    • 納羅基斯目標

9. 口服藥物引起的鴉片類藥物便秘市場

  • 液體
    • 液體
    • 暫停
  • 固態的
    • 膠囊
    • 藥片

10. 鴉片類藥物引起的便秘市場－直腸給藥

  • 灌腸
  • 栓劑

11. 鴉片類藥物引起的便秘市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

12. 鴉片類藥物引起的便秘市場（依組別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各國鴉片類藥物引起的便秘市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AstraZeneca plc
    • Shionogi & Co., Ltd.
    • H. Lundbeck A/S
    • Bausch Health Companies Inc.
    • Mundipharma International Limited
    • Merck & Co., Inc.
    • Valinor Pharma, LLC
Product Code: MRR-742BD5182A30

The Opioid Induced Constipation Market is projected to grow by USD 119.94 million at a CAGR of 6.94% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 70.10 million
Estimated Year [2025] USD 75.03 million
Forecast Year [2032] USD 119.94 million
CAGR (%) 6.94%

Contextualizing opioid induced constipation as an urgent clinical quality and patient experience priority that demands integrated care pathways and product innovation

Opioid induced constipation (OIC) represents a persistent and complex complication of opioid therapy that affects patient adherence, quality of life, and clinical outcomes. As opioid prescribing remains an essential component of pain management across acute and chronic care settings, OIC emerges as a predictable adverse effect that requires proactive assessment and integrated management strategies. Clinicians, payers, and product developers must reconcile the dual imperatives of effective analgesia and maintaining gastrointestinal function, prompting new clinical pathways and innovation in supportive therapies.

Contemporary practice increasingly emphasizes early risk identification, tailored prophylactic regimens, and a stepped approach to intervention that begins with lifestyle counseling and laxative selection and escalates to targeted agents when necessary. Alongside clinical practices, payers and health systems are re-evaluating formulary placement, reimbursement policies, and value frameworks to incorporate patient-reported outcomes related to bowel function. This introduction sets the stage for a focused examination of therapeutic classes, administration formats, regional market drivers, and strategic considerations for stakeholders seeking to improve patient outcomes while preserving appropriate opioid access.

Rapid evolution in clinical practice, payer engagement, digital monitoring, and formulation innovation catalyzing a new era in management of opioid induced constipation

The landscape of OIC management is undergoing several transformative shifts driven by clinical, regulatory, and patient-experience imperatives. First, there is a marked clinical pivot toward mechanism-targeted therapies that address receptor-mediated constipation without compromising central analgesia. This shift has altered prescribing patterns and prompted clinicians to consider peripherally acting mu-opioid receptor antagonists earlier in the treatment continuum. Second, patient expectations and digital health engagement are reshaping how constipation is reported, monitored, and managed; mobile symptom tracking and telemedicine follow-up are increasingly integrated into care plans, enabling more responsive therapy adjustments.

Third, payer engagement is intensifying as health systems seek to quantify the downstream effects of OIC on hospital readmissions, length of stay, and adherence to opioid regimens. Consequently, formularies and utilization management are evolving to reflect evidence around clinical benefit and real-world effectiveness. Fourth, innovation in dosage forms and combination therapies is expanding therapeutic choices for clinicians. Finally, interdisciplinary collaboration between pain specialists, gastroenterologists, and primary care providers is becoming more common, supporting comprehensive pathways that begin at opioid initiation and continue through routine follow-up and escalation where indicated. Together, these shifts create an environment in which clinical efficacy, patient-centered outcomes, and economic considerations intersect to guide future investment and practice patterns.

How 2025 tariff changes reshaped pharmaceutical sourcing, supply chain resilience, and procurement strategies affecting availability and cost dynamics of OIC therapies

Tariff policies and cross-border trade considerations introduced in 2025 have exerted measurable pressure on supply chains for pharmaceutical ingredients and finished dosage forms relevant to OIC therapies. Manufacturers faced with increased import costs have responded through supply chain rationalization, localized sourcing strategies, and tactical inventory adjustments to mitigate pricing volatility and maintain continuity of supply. These responses have also accelerated industry interest in regional manufacturing hubs to reduce exposure to tariff-driven cost swings and to support more resilient distribution networks.

In parallel, procurement teams at hospitals and distributors have adapted contracting strategies to prioritize multi-source suppliers and longer-term agreements that buffer short-term tariff fluctuations. Clinical stakeholders have observed intermittent impact on availability of specific branded and generic products, particularly in specialized formulations, prompting substitutions to alternative agents or administration routes where clinically appropriate. Policy-driven cost pressures have encouraged a renewed focus on cost-effectiveness assessments, negotiation of value-based agreements, and increased scrutiny of supply chain transparency. Collectively, the tariff environment of 2025 has reinforced the need for flexible sourcing strategies, proactive stakeholder communication, and integrated contingency planning across the OIC therapeutic ecosystem.

Segmented therapeutic and formulation profiles uncover distinct clinical, tolerability, and commercial dynamics across combination therapies, laxative classes, receptor antagonists, and administration routes

A detailed segmentation approach reveals important clinical and commercial differentials across therapeutic classes and administration formats that inform targeted strategies. When viewed through the lens of product type, the market comprises combination therapies that blend agents for synergistic bowel regulation, traditional laxatives subdivided into osmotic agents, stimulant options, and stool softeners that address different mechanisms of action, and peripherally acting mu-opioid receptor antagonists which include alvimopan, methylnaltrexone, naldemedine, and naloxegol as distinct molecular options with differing pharmacokinetic profiles and clinical indications. These product-level distinctions have practical implications for clinical pathways, prescribing preference, and real-world tolerability.

When considering oral administration channels, formulations segregate into liquid and solid formats; liquid presentations include solutions and suspensions that can support titration and pediatric or dysphagic populations, while solid formats encompass capsules and tablets favored for convenience and adherence in ambulatory care. Rectal interventions retain a niche yet critical role, delivered as enemas and suppositories that offer rapid effect in acute care and palliative contexts. Cross-segment considerations such as patient demographics, comorbidities, route-specific onset of action, and formulation tolerability guide clinician choice and payer positioning. Understanding these layered segmentation dynamics enables more precise clinical guideline development, formulary strategies, and commercial planning that align product characteristics to real-world patient needs.

Regional differences in healthcare systems, reimbursement priorities, and prescribing norms that determine uptake, access strategies, and clinical adoption patterns across global markets

Regional dynamics exert substantial influence on access, clinician behavior, and policy responses to opioid induced constipation, with distinct drivers in the Americas, Europe Middle East & Africa, and Asia-Pacific regions. In the Americas, integrated health systems and large private payer markets emphasize clinical outcomes and patient-reported measures, driving early adoption of targeted pharmacotherapies and supporting investments in adherence programs and digital monitoring. Regulatory pathways in this region also influence label indications, which in turn affect clinical utilization and reimbursement discussions.

In Europe, Middle East & Africa, regional heterogeneity shapes practice patterns; some national systems prioritize cost-containment and centralized procurement while others emphasize clinical guideline alignment and specialist referral pathways. These differences create varied uptake patterns for advanced agents versus traditional laxatives. In the Asia-Pacific region, rapid growth in healthcare infrastructure, expanding access to specialist care, and evolving regulatory frameworks are creating new opportunities for adoption of targeted therapies, while cost-sensitivity and variable availability of formulations inform local prescribing strategies. Across all regions, demographic trends, opioid prescribing norms, and health system priorities interact to determine how therapies are positioned and how stakeholder education and access initiatives are implemented.

Competitive dynamics shaped by established pharmaceutical players, specialty innovators, generics, and digital health collaborators driving differentiated access and evidence strategies

The competitive landscape for OIC therapies is shaped by established pharmaceutical innovators, specialty biotech entrants, and generic manufacturers, each contributing to therapeutic choice and market evolution. Large manufacturers bring scale, broad distribution networks, and established relationships with payers and providers, enabling rapid commercialization of new agents and supporting extensive post-marketing evidence generation. Specialty biotech firms often drive innovation with novel molecules and mechanism-focused approaches that can shift treatment paradigms, particularly when supported by strong clinical differentiation and targeted labeling.

Generic manufacturers and contract producers contribute to price competition and accessibility, particularly in regions and care settings where cost is a primary barrier. In addition to traditional competitors, non-pharmaceutical players such as digital therapeutics and remote monitoring vendors are influencing patient engagement and real-world outcome measurement, creating opportunities for partnership. Across these actors, success is increasingly determined by the ability to generate real-world evidence, demonstrate patient-centered benefits, and navigate complex payer environments to secure favorable reimbursement and formulary placement.

Practical and strategic recommendations for stakeholders to strengthen evidence generation, patient access, formulation diversity, supply resilience, and collaborative commercialization approaches

Leaders across industry, clinical practice, and payer organizations should take coordinated actions to improve patient outcomes and commercial performance in OIC management. First, prioritize generation and dissemination of real-world evidence that links symptom control to meaningful outcomes such as adherence to analgesic regimens and reduction in healthcare utilization; such evidence strengthens value dialogues with payers and prescribers. Second, invest in patient-centric formulation development and access models that address specific needs, including liquid options for vulnerable populations and rectal formulations for acute care settings, while considering opportunities for combination therapies that streamline care.

Third, enhance cross-stakeholder education initiatives that align prescriber knowledge, nursing practice, and patient self-management, leveraging digital tools for symptom tracking and remote follow-up. Fourth, reinforce supply chain resilience by diversifying sourcing, establishing regional manufacturing partnerships, and negotiating flexible procurement contracts to mitigate policy-driven disruptions. Finally, explore strategic collaborations between innovators, generics, and digital health firms to combine therapeutic efficacy with improved adherence and patient engagement. These actions, taken together, will enable more effective integration of OIC management into holistic pain care pathways and strengthen commercial positioning.

A transparent multi-source research approach integrating clinical evidence, regulatory review, expert consultation, and supply chain analysis to produce validated insights and practical implications

This research synthesizes a multi-source methodology combining peer-reviewed clinical literature, regulatory documentation, expert clinician interviews, payer policy analysis, and primary stakeholder consultations to construct a balanced and actionable perspective on OIC management. Clinical literature and guideline reviews were prioritized to establish accepted standards of care and mechanistic rationale for therapeutic classes, while regulatory documents provided context on labeling, indications, and safety communications. Expert interviews with pain specialists, gastroenterologists, formulary managers, and pharmacists enriched the analysis with real-world practice patterns, tolerability considerations, and procurement dynamics.

Complementing qualitative inputs, a structured review of product portfolios, formulation availability, and supply chain arrangements informed commercial and operational observations. The methodology emphasized triangulation across sources to validate findings and identify convergent themes, ensuring that insights reflect both clinical realities and operational constraints. Throughout the research process, care was taken to avoid reliance on single-source data and to document assumptions and limitations transparently, enabling readers to interpret findings within the appropriate evidentiary context.

Concluding perspective that integrates clinical imperatives, evidence priorities, and strategic actions to reduce patient burden while preserving appropriate opioid access

Opioid induced constipation stands at the intersection of clinical need, patient experience, and commercial opportunity. The convergence of targeted pharmacology, evolving payer expectations, and digital patient engagement tools presents a compelling environment for stakeholders to reframe OIC management as an integral component of responsible opioid therapy. Clinicians are positioned to incorporate proactive prevention and earlier escalation strategies, while manufacturers and payers must collaborate to align value demonstration with access pathways that meet diverse patient needs.

Looking ahead, success will favor actors who can integrate robust clinical evidence, adaptable supply models, and patient-centric delivery formats into coherent commercial and clinical strategies. By prioritizing real-world outcomes, formulation diversity, and system-level collaboration, stakeholders can reduce the burden of OIC on patients and health systems while preserving necessary access to opioid analgesia. This conclusion underscores the imperative for coordinated action across clinical, commercial, and policy domains to improve both quality of care and patient quality of life.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising uptake of peripherally acting mu-opioid receptor antagonists in hospitalized patients with chronic cancer pain management
  • 5.2. Expansion of novel oral small molecule treatments targeting opioid-induced constipation symptoms in outpatient settings
  • 5.3. Integration of digital therapeutics and mobile health apps for real-time monitoring of opioid-induced constipation severity
  • 5.4. Increasing investment in extended-release combination opioid formulations with built-in constipation mitigation mechanisms
  • 5.5. Impact of recent FDA label expansions for naloxegol and naldemedine on opioid-induced constipation treatment algorithms
  • 5.6. Market penetration of linaclotide and plecanatide beyond irritable bowel syndrome for opioid-induced constipation off-label use
  • 5.7. Adoption of patient-centric reimbursement models to improve access to expensive opioid-induced constipation therapies
  • 5.8. Influence of clinical guidelines advocating early intervention for opioid-induced constipation among palliative care populations
  • 5.9. Role of telemedicine consultations in optimizing management strategies for opioid-induced constipation in rural healthcare settings
  • 5.10. Emergence of over-the-counter opioid-induced constipation remedies and their effect on prescription market dynamics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Opioid Induced Constipation Market, by Product Type

  • 8.1. Combination Therapies
  • 8.2. Laxatives
    • 8.2.1. Osmotic Laxatives
    • 8.2.2. Stimulant Laxatives
    • 8.2.3. Stool Softeners
  • 8.3. Peripherally Acting Mu-Opioid Receptor Antagonists
    • 8.3.1. Alvimopan
    • 8.3.2. Methylnaltrexone
    • 8.3.3. Naldemedine
    • 8.3.4. Naloxegol

9. Opioid Induced Constipation Market, by Oral

  • 9.1. Liquid
    • 9.1.1. Solutions
    • 9.1.2. Suspensions
  • 9.2. Solid
    • 9.2.1. Capsules
    • 9.2.2. Tablets

10. Opioid Induced Constipation Market, by Rectal

  • 10.1. Enemas
  • 10.2. Suppositories

11. Opioid Induced Constipation Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Opioid Induced Constipation Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Opioid Induced Constipation Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. AstraZeneca plc
    • 14.3.2. Shionogi & Co., Ltd.
    • 14.3.3. H. Lundbeck A/S
    • 14.3.4. Bausch Health Companies Inc.
    • 14.3.5. Mundipharma International Limited
    • 14.3.6. Merck & Co., Inc.
    • 14.3.7. Valinor Pharma, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OPIOID INDUCED CONSTIPATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 275. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 280. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 281. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 282. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 283. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 284. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 285. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 286. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 287. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 288. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 289. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 290. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS OPIOID INDUCED CONS